Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FTC Seeks More Data About Aussie CSL Buy Of Talecris

This article was originally published in PharmAsia News

Executive Summary

The U.S. Federal Trade Commission has requested more information from Australia's CSL about its bid to take over Talecris Biotherapeutics of the United States. CSL, the world's largest maker of plasma products, said such a request was common for mergers that could have U.S. antitrust implications. CSL, which has proposed buying Talecris for $2 billion, said both firms are cooperating with the FTC as it considers the buyout. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts